Respiratory · BronchodilatorRegulatory Approvalregulatorynear-term

Cipla's Albuterol Sulfate ANDA219409 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Cipla4 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:34:38 PM

Assessment confidence: 84% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Cipla's receipt of Abbreviated Approval (AP) status for Albuterol Sulfate is significant as it allows them to enter the competitive respiratory market. This could lead to shifts in market dynamics and pricing strategies among existing players. Regulatory context from FDA (FDA AP — ALBUTEROL SULFATE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (18 high-relevance).

Strategic Assessment

Cipla can now market Albuterol Sulfate, potentially increasing market share and impacting pricing strategies of competitors. The strongest clinical anchor is Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease (ClinicalTrials.gov), moderate corpus alignment. In Respiratory · Bronchodilator, 8 regulatory and 3 competitive items passed relevance filtering for Cipla.

Competitive Pressure

The most relevant competitive pressure comes from Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This approval may enhance Cipla's position in the respiratory market, competing with existing albuterol products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ALBUTEROL SULFATE (ORIG) (FDA). Entity match (cipla); Regulatory pathway relevance (nda). The AP status indicates that Cipla's product meets FDA standards for safety and efficacy, allowing for quicker market entry compared to traditional approval processes.

Key Risks

Elevated medium regulatory exposure for Cipla could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Ralation Between Cardiorespiratory Fitness and Mean Corrected Intraocular Pressure) could weigh on Cipla through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Cipla's entry into the market with Albuterol Sulfate may increase competition, potentially affecting the market share and pricing of established albuterol products.
Upside for Cipla may improve if Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Cipla can now market Albuterol Sulfate, potentially increasing market share and impacting pricing strategies of competitors.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch date and market entry of Cipla's Albuterol Sulfate product.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ALBUTEROL SULFATE (ORIG)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALBUTEROL SULFATE (ORIG)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Respiratory Muscle Strength Training to Prevent Respiratory Muscle Weakness in Adults Newly Diagnosed With Breast Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Ralation Between Cardiorespiratory Fitness and Mean Corrected Intraocular Pressure
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Optimisation of High Flow Oxygen Therapy Settings During Hypoxaemic Respiratory Distress Based on Non-contact Measurement of Lung Volumes by Depth Camera
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised cr
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Cipla
Albuterol Sulfate

Commercial impact

medium

Cipla's entry into the market with Albuterol Sulfate may increase competition, potentially affecting the market share and pricing of established albuterol products.

Regulatory impact

medium

The AP status indicates that Cipla's product meets FDA standards for safety and efficacy, allowing for quicker market entry compared to traditional approval processes.

What to watch

Monitor for the launch date and market entry of Cipla's Albuterol Sulfate product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.